Acrycoat RS30D represents a premium-quality ammonia methacrylate copolymer dispersion that strictly conforms to European Pharmacopoeia Type B specifications. This 30% milky liquid ...

Acrycoat RS30D represents a premium-quality ammonia methacrylate copolymer dispersion that strictly conforms to European Pharmacopoeia Type B specifications. This 30% milky liquid polymer is specifically engineered for pH-independent swelling and permeability characteristics, ensuring consistent performance in sustained-release pharmaceutical formulations. The product delivers reliable film formation and controlled drug release properties, making it an indispensable excipient for manufacturers developing advanced oral dosage forms. Its versatility combined with compliance to international standards establishes it as a trusted solution for formulators seeking stability, predictability, and efficacy in drug delivery systems across global markets.

This advanced polymer dispersion finds extensive application throughout the pharmaceutical industry, particularly in oral solid dosage manufacturing where controlled release mechanisms are paramount. It serves as an ideal component for creating sustained-release tablets, capsules, and pellets that require precise API release regardless of gastrointestinal pH variations. Various sectors including generic drug manufacturing, innovative pharmaceutical research and development, and contract production facilities utilize Acrycoat RS30D to enhance product performance, ensure regulatory compliance, and improve patient adherence through optimized release profiles. The applications further extend to specialized areas such as veterinary medicines and nutraceuticals where controlled release functionality proves critical for therapeutic success.

Acrycoat RS30D delivers substantial business value through its exceptional reliability, consistent quality, and performance predictability. The polymer significantly reduces formulation risks by maintaining consistent swelling and permeability characteristics across all pH levels, thereby minimizing batch failures and ensuring reproducible manufacturing results. Its strict adherence to EP specifications guarantees regulatory acceptance across international markets, streamlining product approval processes and reducing time-to-market. The polymer's adaptability allows for tailored release kinetics, providing competitive advantages in developing differentiated pharmaceutical products. By enhancing drug efficacy and improving patient outcomes, it establishes long-term customer trust and supports sustainable market success for pharmaceutical companies.

Key Features:
- pH-independent swelling and permeability ensuring consistent performance across varying pH conditions
- Full compliance with EP specifications for Ammonia Methacrylate Copolymer Type B
- 30% milky dispersion formulation for easy handling and application processes
- Specifically designed for sustained-release formulations across multiple dosage forms
- High-quality reliable excipient with exceptional batch-to-batch consistency

Benefits:
- Consistent drug delivery performance independent of gastrointestinal pH variations
- Regulatory compliance assurance with international pharmacopoeia standards
- User-friendly dispersion format simplifying manufacturing and processing
- Versatile application across various sustained-release dosage form developments
- Reliable quality and performance reducing formulation risks and batch failures